Skip to main content

Table 1 Patient characteristics

From: PSMA-ligand uptake can serve as a novel biomarker in primary prostate cancer to predict outcome after radical prostatectomy

Characteristic Patients
Age (years), median (IQR), n = 186 68 (61–72)
iPSA (ng/ml), median (IQR), n = 184a 9.7 (6.5–15.1)
Administered 68Ga-PSMA-11 activity (MBq), median (IQR), n = 185b 139 (112–156)
Time PET to RP (day), median (IQR), n = 186 26 (13–46)
Gleason score in surgical specimen, no. (%), n = 186
 6 11 (5.9%)
 7a 63 (33.9%)
 7b 59 (31.7%)
 8 28 (15.1%)
 9 25 (13.4%)
Pathological stage, no. (%), n = 186
 pT status
  2a 11 (5.9%)
  2b 10 (5.4%)
  2c 71 (38.2%)
  3a 49 (26.3%)
  3b 44 (23.7%)
  4 1 (0.5%)
 pN status
  0 154 (82.8%)
  1 32 (17.2%)
Surgical margin, no. (%), n = 180c
 Negative 152 (84.4%)
 Positive 28 (15.6%)
  1. iPSA initial PSA, IQR interquartile range, PET positron emission tomography, PSA prostate-specific antigen, RP radical prostatectomy
  2. aiPSA of two patients were unavailable
  3. bThe injected dose of 68Ga-PSMA-11 from one patient was unavailable
  4. cThe status of surgical margin from six patients were unavailable